Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Proteolysis-targeting chimeric molecules (PROTACs), which attract much more attention today, may be a potential way to treat cancer. PROTACs are made up of ligands of target proteins, E3 ligase recruiting elements and linkers. PROTACs can hijack the intracellular inherent ubiquitin proteasome system in cells to degrade different target proteins. PROTACs targeting different cancer-related proteins have been successfully developed and outperform small inhibitors, the traditional way of treating cancer. In this review, we focus on PROTACs targeting cancer-related proteins and their superiority over inhibitors. Copyright © 2020 Elsevier Masson SAS. All rights reserved.


Xin Zhou, Ru Dong, Jin-Yang Zhang, Xin Zheng, Li-Ping Sun. PROTAC: A promising technology for cancer treatment. European journal of medicinal chemistry. 2020 Oct 01;203:112539

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 32698111

View Full Text